1 / 20

Clinical Cancer Advances 2011

Clinical Cancer Advances 2011. ASCO’s seventh annual Clinical Cancer Advances report identifies this year’s most significant clinical cancer advances Highlights 12 most important advances, along with 42 other notable advances in prevention and screening, treatment, and survivorship

river
Download Presentation

Clinical Cancer Advances 2011

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical Cancer Advances 2011 • ASCO’s seventh annual Clinical Cancer Advances report identifies this year’s most significant clinical cancer advances • Highlights 12 most important advances, along with 42 other notable advances in prevention and screening, treatment, and survivorship • Overseen by 18-member editorial board of oncologists • Complete 2011 CCA report is available: • Interactive PDF at www.cancer.net/cca • Published in the Journal of Clinical Oncology, www.jco.org

  2. Top Advances of 2011 • New therapy for advanced melanoma • CT screening reduced lung cancer deaths • FDA approved new therapies for 2 hard-to-treat cancers: lung cancer and melanoma • High-dose chemotherapy regimen improves survival in children with neuroblastoma • Aromatase inhibitor reduced the risk of a first breast cancer

  3. Top 12 Advances 1. BRAF Inhibitor Improves Survival in Advanced Melanoma • Phase III trial showed vemurafenib (Zelboraf®) improved overall survival in patients with advanced melanoma when compared to standard therapy • The therapy targets a common mutation in melanoma in the BRAF gene • About ½ of patients have tumors that carry this mutation • Vemurafenib was FDA approved in August 2011

  4. Top 12 Advances 2. Low-Dose CT Scan Reduces Lung Cancer Death Rate in People at High Risk • National screening trial of more than 50,000 current- and former-heavy smokers • Found three annual low-dose CT scans reduced risk of dying from lung cancer by 20% • Results were compared patients screened with three annual chest X-rays

  5. Top 12 Advances 3. FDA Approves Crizotinib (Xalkori®) for Lung Cancer • FDA approved crizotinib in August 2011 for patients with advanced non-small cell lung cancer whose tumors harbor a specific type of alteration in the anaplastic lymphoma kinase (ALK) gene • In studies, the treatment was found to improve survival by 31 percent after two years

  6. Top 12 Advances 4. First-Line Ipilimumab Plus Chemotherapy Improves Survival in Metastatic Melanoma • Phase III study found ipilimumab (Yervoy®) plus dacarbazine improved overall survival by 2 months in patients with previously untreated metastatic melanoma, compared to chemo alone • Ipilimumab is an immune therapy that activates the immune system’s T cells • Ipilimumab was FDA approved in March 2011

  7. Top 12 Advances 5. New Chemo Regimen Boosts Survival for Children and Young Adults with ALL • Phase III Children’s Oncology Group trial of nearly 2,500 children and young adults with acute lymphoblastic leukemia (ALL) • Showed methotrexate given in large, consistent doses, rather than gradually increasing doses of the standard regimen, was more effective in preventing relapse and improving survival • Findings set new standard of care and pushed cure rates for pediatric ALL patients to more than 80%

  8. Top 12 Advances 6. Exemestane Reduces Risk of Invasive Breast Cancer • Phase III trial of the aromatase inhibitor (AI) exemestane compared with placebo • Found the AI reduced risk of developing breast cancer in high-risk, postmenopausal women • First conclusive evidence that an AI reduced risk of a first breast cancer

  9. Top 12 Advances 7. Bevacizumab Delays Progression in Recurrent Ovarian Cancers • Two randomized Phase III trials found women with recurrent ovarian cancer who received combination therapy lived significantly longer without their disease worsening than those who received chemo alone • First trial (OCEANS) found patients treated with bevacizumab lived a median of four months longer without disease progression than those with chemo alone

  10. Top 12 Advances 8. Bevacizumab Delays Progression in Recurrent Ovarian Cancers • Two randomized Phase III trials found women with recurrent ovarian cancer who received combination therapy lived significantly longer without their disease worsening than those who received chemo alone • First trial (OCEANS) found patients treated with bevacizumab lived a median of four months longer without disease progression than those with chemo alone • Second trial data suggested bevacizumab added to standard carboplatin and paclitaxel chemo for newly diagnosed ovarian cancer patients, particularly those with more aggressive disease, helps women live longer than with chemo alone

  11. Top 12 Advances 9. Imatinib Therapy Improves Survival for High-Risk GIST • Phase III trial showed 3 years of treatment with imatinib (Gleevec®) after surgery in patients with high-risk gastrointestinal stromal tumors (GIST) significantly improved overall and recurrence-free survival compared to one year of treatment • Findings could result to three-year course of therapy becoming new standard of care for patients at risk for relapse

  12. Top 12 Advances 10. New Chemo Regimen Improves Survival in Children with Neuroblastoma • Phase III trial showed a new high-dose combination of chemotherapy drugs improved survival for children with high-risk metastatic neuroblastoma • At 3 years, event-free survival rate for patients treated with intense dosing of busulphan-melphalan was 49% compared to 33% for the standard chemotherapy drugs carboplatin, etoposide and melphalan • These findings establish a new standard of care for high-risk neuroblastoma

  13. Top 12 Advances 11. RNI Decreases Recurrence in Women with Early Breast Cancer • Analysis of a randomized phase III trial found adding radiation to the regional lymph nodes reduces risk of cancer recurrence both near the tumor and in other parts of the body • Findings apply to women with early-stage breast cancer who have one to three cancer-positive lymph nodes (or high-risk node-negative breast cancer)

  14. Top 12 Advances 12. Abiraterone Acetate FDA Approved for Prostate Cancer • The FDA approved the oral agent abiraterone acetate (Zytiga®) in combination with prednisone for patients with metastatic hormone-refractory prostate cancer who have received prior treatment with docetaxel • The drug works by blocking production of male sex hormones that fuel the growth of prostate tumors

  15. 2011 Cancer Policy Developments • Progress against cancer • Transforming clinical cancer research • Progress made in revitalizing federally funded clinical trials • Potential impact of healthcare reform on cancer disparities • Severe cancer drug shortages gain attention of media and congress ASCO Blueprint: www.asco.org/blueprint

  16. 2011 Cancer Policy Developments • Severe cancer drug shortages gain attention of media and congress • ASCO takes steps to improve advanced cancer care planning • Research highlights potential solutions for oncology workforce shortages • United Nations Summit addresses cancer crisis in developing countries

  17. ASCO Resources Cancer.net www.cancer.net ASCO Guidelines www.asco.org/guidelines Conquer Cancer Foundation www.ccf.org ASCO Connection http://connection.asco.org

  18. ASCO Resources Cancer Progress www.cancerprogress.net The cancerprogress.net site provides a dynamic and interactive history of progress against cancer, expert perspective on remaining challenges and other useful tools

  19. ASCO’s Annual Report on Progress Against Cancerwww.cancer.net/cca For additional information, contact Susie Tappouni in ASCO’s Communications Department: susie.tappouni@asco.org571-483-1355

More Related